Independent Advisor Alliance Grows Holdings in Agilent Technologies, Inc. $A

Independent Advisor Alliance grew its stake in Agilent Technologies, Inc. (NYSE:A) by 215.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,954 shares of the medical research company’s stock after buying an additional 5,432 shares during the period. Independent Advisor Alliance’s holdings in Agilent Technologies were worth $1,082,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Massachusetts Financial Services Co. MA lifted its holdings in shares of Agilent Technologies by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company’s stock worth $1,925,064,000 after acquiring an additional 1,713,216 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Agilent Technologies by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company’s stock worth $1,203,990,000 after acquiring an additional 433,342 shares during the last quarter. Generation Investment Management LLP lifted its holdings in shares of Agilent Technologies by 10.1% in the 3rd quarter. Generation Investment Management LLP now owns 6,357,953 shares of the medical research company’s stock worth $816,043,000 after acquiring an additional 582,093 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Agilent Technologies by 15.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,708,591 shares of the medical research company’s stock worth $347,685,000 after acquiring an additional 354,480 shares during the last quarter. Finally, Troy Asset Management Ltd lifted its holdings in shares of Agilent Technologies by 0.3% in the 3rd quarter. Troy Asset Management Ltd now owns 2,404,161 shares of the medical research company’s stock worth $308,574,000 after acquiring an additional 6,341 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on A shares. Barclays lowered their price objective on shares of Agilent Technologies from $150.00 to $140.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Morgan Stanley lowered their price objective on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Wells Fargo & Company lowered their price objective on shares of Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating for the company in a report on Thursday, February 26th. UBS Group lowered their price objective on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Finally, Wall Street Zen lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $163.71.

Agilent Technologies Stock Down 1.4%

Shares of NYSE A opened at $111.69 on Friday. The company has a current ratio of 2.07, a quick ratio of 1.59 and a debt-to-equity ratio of 0.44. Agilent Technologies, Inc. has a 12 month low of $107.07 and a 12 month high of $160.27. The firm has a market capitalization of $31.56 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 2.38 and a beta of 1.22. The firm has a fifty day simple moving average of $115.06 and a two-hundred day simple moving average of $130.68.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing the consensus estimate of $1.37 by ($0.01). Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The company had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. During the same quarter last year, the company posted $1.31 earnings per share. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Equities analysts expect that Agilent Technologies, Inc. will post 5.95 earnings per share for the current year.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.